Vical Inc (VICL): Gary A Lyons , director of Vical Inc purchased 7,078 shares on Jun 3, 2016. The Insider buying transaction was reported by the company on Jun 6, 2016 to the Securities and Exchange Commission. The shares were purchased at $4.39 per share for a total value of $31,088.70 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 17, 2016, Lawrence Russell Smith (VP, Vaccine Research) sold 8,750 shares at $0.41 per share price.On Feb 22, 2016, Anthony Alan Ramos (VP, Chief Accounting Officer) sold 7,500 shares at $0.33 per share price.Also, On Jan 13, 2016, Vijay B Samant (President & CEO) sold 59,737 shares at $0.35 per share price.On Jul 15, 2015, Igor Bilinsky (Sr VP, Corporate Development) sold 1,258 shares at $0.70 per share price.
Vical Incorporated: On Friday, Jun 3, 2016 heightened volatility was witnessed in Vical Incorporated which led to swings in the share price. The shares opened for trading at $4.34 and hit $4.43 on the upside , eventually ending the session at $4.393, with a gain of 0.30% or 0.013 points. The heightened volatility saw the trading volume jump to 52,440 shares. The 52-week high of the share price is $15.5 and the company has a market cap of $40 M . The 52-week low of the share price is at $2.808.
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has three active independent or partnered development programs in the areas of infectious disease consisted of: Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial using its Vaxfectin formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2) a cause of recurrent genital herpes and a completed preclinical program with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant to prevent CMV infection before and during pregnancy.